Related Experiment Video

Updated: Aug 2, 2026

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
05:53

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Published on: July 24, 2013

Analysis of causes for liver function deterioration in patients with HIV/HCV co-infection

Yong-Hong Zhang1, Xin-Yue Chen, Yan Jiang

  • 1Department of Infectious Diseases, You'an Hospital, Beijing 100054, China.

Hepatobiliary & Pancreatic Diseases International : HBPD INT
|November 30, 2004
PubMed

Insights

Hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1) co-infection accelerates liver disease progression. HIV/HCV co-infection significantly impacts immune function and leads to earlier liver abnormalities compared to HCV infection alone.

Area of Science:

  • Hepatology
  • Immunology
  • Virology

Background:

  • Hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1) co-infection is prevalent in individuals with hemophilia and among drug abusers.
  • Understanding the interaction between HIV and HCV is crucial for managing disease progression.

Purpose of the Study:

  • To assess the impact of HIV/HCV co-infection on liver disease progression and immune function compared to HCV infection alone.
  • To investigate differences in liver function, pathological changes, and immune markers between co-infected and HCV-monoinfected patients.

Main Methods:

  • Retrospective comparison of liver function, pathological changes, infection duration, and immune status in 82 HIV/HCV co-infected patients and 62 HCV-monoinfected patients.
  • Assessment of qualitative HCV-RNA and HCV antibody status.

Main Results:

  • Liver abnormality appeared 8 years earlier in the HIV/HCV co-infection group (P<0.001).
  • Significantly lower CD4+ and CD8+ T cell counts were observed in the HIV/HCV group compared to the HCV group (P<0.001).
  • A higher ratio of patients positive for both HCV-RNA and HCV antibody was noted in the co-infected group (P=0.043).

Conclusions:

  • HIV/HCV co-infection accelerates the deterioration of hepatitis C.
  • The observed acceleration is likely attributed to HIV's detrimental effects on cellular and humoral immunity.
Abstract

More Related Videos

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis10:12

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis

Published on: September 11, 2019

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...